Macquarie Group
FRTX

Macquarie Group’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Macquarie Group’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22
Closed -$8K – 2120
2018
Q4 		$8K Sell
22
-24
-52% -$9.41K ﹤0.01% 1972
2018
Q3 		$20K Buy
+46
New +$19.4K ﹤0.01% 1908
2018
Q2 		– Sell
-348
Closed -$159K – 2292
2018
Q1 		$159K Buy
+348
New +$173K ﹤0.01% 1775

Other funds holding FRTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's FRTX Position: Q1 2019 in Review

Macquarie Group sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q1 2019, closing a stake of 22 shares — an estimated $8K sold.

Macquarie Group first reported a position in FRTX in Q1 2018 and held it in 3 quarters. The position peaked at $159K in Q1 2018. 30 funds tracked by Wall St. Rank hold FRTX as of Q1 2019.

  • Macquarie Group reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 22 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $8K.
  • Macquarie Group first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Macquarie Group's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $159K in Q1 2018.
  • 30 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.